Literature DB >> 11596960

Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival.

K Tada1, S Shiraishi, T Kamiryo, H Nakamura, H Hirano, J Kuratsu, M Kochi, H Saya, Y Ushio.   

Abstract

OBJECT: The most frequent genetic abnormality in human malignant gliomas is loss of heterozygosity (LOH) on chromosome 10. Candidate genes on chromosome 10 that are associated with the prognosis of patients with anaplastic astrocytoma (AA) and glioblastoma (GBM) were evaluated.
METHODS: The authors used 12 fluorescent microsatellite markers on both arms of chromosome 10 to study LOH in 108 primary astrocytic tumors. The LOH on chromosome 10 was observed in 11 (32%) of 34 AAs and 34 (56%) of 61 GBMs. No LOH was detected in 13 low-grade gliomas. Loss of heterozygosity was not detected in any AA in the seven patients younger than 35 years, but it was discovered in 41% of the patients older than 35 years. The prognostic significance of LOH at each locus was evaluated in 89 patients older than 15 years; 33 (37%) had supratentorial AAs and 56 (63%) had supratentorial GBMs. The Cox proportional hazards model, adjusted for patient age at surgery, the preoperative Karnofsky Performance Scale score, and the extent of surgical resection revealed that LOH on marker D10S209 near the FGFR2 and DMBT1 genes was significantly associated with shorter survival in patients with AA. The LOH on markers D10S215 and D10S541, which contain the PTEN/MMAC1 gene between them, was significantly associated with shorter survival in patients with GBM.
CONCLUSIONS: In the present study it is found that LOH on chromosome 10 is an age-dependent event for patients with AAs and that LOH on marker D10S209 near the FGFR2 and DMBT1 loci is a significantly unfavorable prognostic factor. It is also reported that LOH on the PTEN/MMAC1 gene is a significantly unfavorable prognostic factor in patients with GBM.

Entities:  

Mesh:

Year:  2001        PMID: 11596960     DOI: 10.3171/jns.2001.95.4.0651

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Detailed characterization of alterations of chromosomes 7, 9, and 10 in glioblastomas as assessed by single-nucleotide polymorphism arrays.

Authors:  Inês Crespo; Ana Luísa Vital; Ana Belen Nieto; Olinda Rebelo; Hermínio Tão; Maria Celeste Lopes; Catarina Resende Oliveira; Pim J French; Alberto Orfao; María Dolores Tabernero
Journal:  J Mol Diagn       Date:  2011-08-30       Impact factor: 5.568

3.  Cancer stem cells from a rare form of glioblastoma multiforme involving the neurogenic ventricular wall.

Authors:  Shengwen Calvin Li; Long T Vu; Hector W Ho; Hong Zhen Yin; Vic Keschrumrus; Qiang Lu; Jun Wang; Heying Zhang; Zhiwei Ma; Alexander Stover; John H Weiss; Philip H Schwartz; William G Loudon
Journal:  Cancer Cell Int       Date:  2012-09-20       Impact factor: 5.722

4.  Treatment of glioblastoma in elderly patients.

Authors:  Florian Stockhammer
Journal:  CNS Oncol       Date:  2014-03

5.  Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Authors:  Silke Wemmert; Ralf Ketter; Jörg Rahnenführer; Niko Beerenwinkel; Martin Strowitzki; Wolfgang Feiden; Christian Hartmann; Thomas Lengauer; Florian Stockhammer; Klaus D Zang; Eckart Meese; Wolf-Ingo Steudel; Andreas von Deimling; Steffi Urbschat
Journal:  Neoplasia       Date:  2005-10       Impact factor: 5.715

6.  The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.

Authors:  Robert W Rapkins; Fan Wang; HuyTram N Nguyen; Timothy F Cloughesy; Albert Lai; Wendy Ha; Anna K Nowak; Megan P Hitchins; Kerrie L McDonald
Journal:  Neuro Oncol       Date:  2015-04-24       Impact factor: 12.300

7.  Non-enhancing de novo glioblastoma: report of two cases.

Authors:  Aaron A Cohen-Gadol; Michael L DiLuna; Sergei I Bannykh; Joseph M Piepmeier; Dennis D Spencer
Journal:  Neurosurg Rev       Date:  2004-07-28       Impact factor: 3.042

8.  Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products.

Authors:  Hua-Chuan Zheng; Yi-Ling Li; Jin-Min Sun; Xue-Fei Yang; Xiao-Han Li; Wei-Guo Jiang; Yin-Chang Zhang; Yan Xin
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

9.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials.

Authors:  Daniel J Brat; Wendy F Seiferheld; Arie Perry; Elizabeth H Hammond; Kevin J Murray; Alan R Schulsinger; Minesh P Mehta; Walter J Curran
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

Review 10.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.